Fixed-dose combinations in type 2 diabetes – Role of the canagliflozin metformin combination

Diabetes, Metabolic Syndrome and Obesity

Volumn 8, Issue , 2015, Pages 287-294

  Fleming, Joshua W ^a   Fleming, Laurie W ^a   Davis, Courtney S ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Canagliflozin metformin; Fixed dose combination (FDC); Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN PLUS METFORMIN; GLIMEPIRIDE PLUS METFORMIN; HEMOGLOBIN A1C; METFORMIN PLUS SITAGLIPTIN; PLACEBO;

BIOEQUIVALENCE; BODY MASS; CONSTIPATION; DEHYDRATION; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FATIGUE; FUNGAL GENITAL INFECTION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERSENSITIVITY; HYPOTENSION; INCIDENCE; MEDICATION COMPLIANCE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLLAKISURIA; POLYDIPSIA; POSITIONAL DIZZINESS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY TRACT INFECTION; VAGINAL PRURITUS; WEIGHT REDUCTION;

EID: 84936951561     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S69282     Document Type: Review

References (26)

1. Danaei G, Finucane MM, Lu Y, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31-40.
2. CDC, Department of Health and Human Services [homepage on the Internet]. National diabetes statistics report, 2014. [updated 2014; cited May 15, 2015]. Available from: http://www.cdc.gov//diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed September 28, 2014.
3. Stumvoll M, Goldstein BJ, van Haeften TW. Pathogenesis of type 2 diabetes. Endocr Res. 2007;32(1-2):19-37.
4. Kroon LA, Williams C. Diabetes mellitus. In: Alldredge BK, Corelli RL, Ernst ME, et al, editors. Koda-Kimble and Young's Applied Therapeutics: The Clinical Use of Drugs. 10th ed. Philadelphia, PA: Lippincott William and Wilkins; 2013:1223.
5. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27(2):384-391.
6. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl 5A):27S-34S.
7. Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood). 2012;31(8):1836-1846.
8. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
9. Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157-1168.
10. Prescott J, Manalo B. Considerations for fixed-dose combination productes in cardiometabolic disease. Pharmacy Times [serial on the Internet] [updated December 12, 2011; cited May 15, 2015]. Available from: http://www.pharmacytimes.com/publications/issue/2011/December2011/Considerations-for-FixedDose-Combination-Products-in-Cardiometabolic-Disease. Accessed February 23, 2015.
11. Truven Health Analytics, Inc. Class Comparison: Antidiabetic Agents. Drug Consults. Micromedex 2.0. Greenwood Village, CO: Truven Health Analytics, Inc.; 2015.
12. FDA approves invokamet. Drugs.com [homepage on the Internet]. [updated August 8, 2014; cited May 15, 2015]. Available from: http://www.drugs.com/newdrugs/fda-approves-invokamet-canagliflozin-metformin-type-2-diabetes-4068.html. Accessed February 13, 2015.
13. Invokamet [package insert]. Titusville, NJ; Janssen Pharmaceuticals; 2014.
14. Nigro SC, Riche DM, Pheng M, Baker WL. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. Ann Pharmacother. 2013;47(10):1301-1311.
15. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011;13(7):669-672.
16. Devineni D, Curtin C, Ariyawansa J, et al. Bioequivalence of canagliflozin/metformin immediate release fixed- dose combination tablets compared with concomitant administration of single components of canagliflozin and metformin in healthy fed participants. J Bioequiv Availab. 2014;6:164-173.
17. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4):372-382.
18. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group. N Engl J Med. 1995;333(9):541-549.
19. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941-950.
20. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582-2592.
21. American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2015;38(Suppl):S41-S48.
22. Qiu R, Capuano G, Meininger G. Efficacy and safety of twice-daily treatment with canagliflozin, A sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J Clin Trans Endocri. 2014;1:54-60.
23. Jarab AS, Almrayat R, Alqudah S, et al. Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes. Int J Clin Pharm. 2014;36(4):725-733.
24. Lopez JM, Annunziata K, Bailey RA, Rupnow MF, Morisky DE. Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence. Patient Prefer Adherence. 2014;8:683-692.
25. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508-2515.
26. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(2): 327-336.